week. Soon after starting to take the drug he noticed generalised muscle weakness and fatigue. The weakness became progressively worse and he had difficulty in ascending stairs and running. After six months his right and subsequently his left foot became numb. On examination the cranial nerves were intact. There was no muscle wasting; there was mild distal weakness in the lower limbs and he had difficulty in rising from a squatting position. Ankle jerks were absent but other reflexes were present and the plantar responses were flexor. Coordination was normal, light touch and temperature sensation were impaired on the dorsum of the feet, vibration sensation was impaired at the toes, and two point discrimination was profoundly impaired on the feet. Haemoglobin, white cell count, erythrocyte sedimentation rate, blood glucose, serum electrolytes, liver function tests, blood urea, serum creatinine, thyroid function studies, glucose tolerance test, serum proteins, antinuclear antibodies, serum vitamin B6, B12, and folic acid concentrations, HIV and hepatitis B serology, serum and urinary electrophoresis, and tests for cryoglobulins and urinary heavy metals and chest radiograph were all normal or negative. Serum CK concentration was 900 U/1. Treatment with simvastatin was withdrawn and on review six weeks later muscle cramps and weakness had improved although he still had the symptoms and signs of peripheral neuropathy. The CK 625 group.bmj.com on June 22, 2017 -Published by 
Abstract
Four patients are described who developed sensorimotor neuropathy while being treated with simvastatin and had complete or partial resolution of clinical abnormalities after withdrawal of treatment. In one case onset was within days of commencing treatment, but in two cases symptoms did not develop for two years. The electrophysiological and pathological features of the neuropathy were those of axonal degeneration. Clinical evidence of proximal and distal weakness and muscle fasciculations and persistent abnormalities of sensory conduction after recovery suggest the possibility of toxic damage to anterior horn cells and dorsal root ganglia. Thirty eight other cases with symptoms suggestive of peripheral neuropathy have been reported to the Australian Adverse Drug Reactions Advisory Committee, 22 of whom recovered after cessation of treatment; in five cases there was recurrence after re-exposure to the drug. Simvastatin should be considered among the causes of peripheral neuropathy, and the drug should be withdrawn if patients receiving it develop muscle weakness or sensory disturbances. ( Electromyography showed evidence of acute denervation in upper and lower limb muscles, with the proximal muscles most severely affected. There were multiform fasciculations in all muscles sampled. Nerve conduction studies showed mild slowing of motor conduction velocities without conduction block and impairment of sensory conduction (tables 1 and 2). Muscle biopsy showed atrophic angular type 1 and 2 fibres with occasional fibres undergoing focal necrosis. Simvastatin treatment was withdrawn and four months later she had completely recovered clinically but nerve conduction studies showed no appreciable change (tables land 2). CASE 4 A woman aged 39 with primary hypercholesterolaemia was started on treatment with simvastatin (10 mg daily), after unsuccessful dietary management. Relevant history included an allergic diathesis with recurrent attacks of urticaria-angioedema, perennial allergic rhinitis, exercise induced asthma, and immediate hypersensitivity to salicylates and tetracyclines. She did not smoke tobacco or drink alcohol.
Within 24 hours of starting the drug she developed pain in her right calf, and later pain in her right groin and pains down both arms. These symptoms were followed by the development of a sensation of pins and needles in her fingertips and later the toes. There were no symptoms of muscle weakness or tenderness. There were no abnormalities on neurological examination; in particular, muscle tone, reflexes, and sensory examination were normal. Routine haematology and biochemistry investigations were unremarkable and serum CK was not raised (48 U/l). There were no abnormalities on electromyography. Motor conduction velocities were towards the lower limit of the normal range and sensory conduction was impaired (tables 1 and 2). An initial diagnosis of painful myopathy and predominantly sensory neuropathy was made. The simvastatin was discontinued after a total dose of 180 mg. There were no clinical or laboratory findings to suggest another cause of her neuropathy. On review three months later, the patient reported almost complete resolution of her symptoms except for the persistence of a few patches of hyperaesthesia over her body. Nerve conduction studies showed improvement in sensory conduction (table 2) . Discussion These -four patients presented with peripheral neuropathy associated with simvastatin treatment. The clinical presentation was with sensory and motor symptoms in case 1, muscle weakness with minor sensory symptoms in cases 2 and 3, and sensory symptoms in case 4. Proximal as well as distal muscle weakness were features in three patients, and two had muscle fasciculations. In three patients the finding of proximal and distal weakness and EMG evidence of widespread chronic partial denervation suggested the possibility of motor neuron disease. In all cases, however, a mixed sensorimotor neuropathy was found on electrophysiological studies. In two of the patients (cases 1 and 4) the onset of symptoms was soon after commencement of simvastatin treatment whereas in the other two (cases 2 and 3) onset was after an interval of two years. Improvement of the neuromuscular symptoms occurred after withdrawal of drug treatment; two patients (cases 3 and 4) reported almost complete resolution of symptoms after four months. In the other cases (cases 1 and 2) improvement was continuing after 15-18 months and there was still considerable residual disability. Because of the close relation of the onset of the peripheral neuropathy and muscle weakness to simvastatin treatment and improvement after its withdrawal, together with the absence of any other cause, it is proposed that peripheral neuropathy in these cases was caused by simvastatin. Cases 1 and 2 may be considered as probable cases of simvastatin neuropathy, and cases 3 and 4 as possible cases. Electrophysiological studies suggested that the underlying pathology was most likely axonal degeneration as there were no features of demyelination and there was electromyographic evidence of denervation and this was confirmed on sural nerve biopsy in case 2. The prominent proximal and distal weakness and incomplete recovery of nerve conduction raise the possibility of a neuronopathy.
The Adverse Drug Reactions Advisory Committee (ADRAC) of Australia reported 22 cases of paraesthesiae and neuropathy associated with simvastatin.7 An updated search of the Australian database of suspected adverse drug reactions to the end of 1993 has increased this total to 38 cases, not including the four cases here. Sensory disturbances included "pins and needles", tingling, burning, numbness, or even frank muscle or joint pain. These symptoms were experienced most often in the limbs and extremities, but other locations such as the face, tongue, and scalp were also affected in some patients. Effects on motor function, which accompanied the sensory symptoms in some patients, included generalised weakness or localised paresis, often associated with myalgia; in one report, muscle atrophy was also noted. Recovery from the adverse reaction occurred in 22 cases, usually after merely stopping drug treatment. Five patients described a recurrence of the adverse reaction on reexposure to the drug. In one patient, the reaction abated when simvastatin was taken as a morning dose; 11 patients had not fully recovered at the time the reports were submitted, and the outcome was not known in five patients.
A possible mechanism by which simvastatin could damage peripheral nerves is through its action of mitochondrical function. 
